Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | LDHB | P07195 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MYC | P01106 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9647534 | 0.88 | ALDH1A1 (0.41) | TSHRKDM4EALDH1A1HSD17B10HPGD | |
| Dexmedetomidine SCHEMBL22476077 | 0.85 | ALDH1A1 (0.41) | TSHRKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL9290481 | 0.85 | KDM4E (0.42) | TSHRKDM4EALDH1A1HSD17B10KMT2A | |
| Medetomidine SCHEMBL22616184 | 0.82 | ADRA2A (0.43) | TSHRNPC1RAB9ACYP1A2CYP3A4 | |
| Dexmedetomidine SCHEMBL22616211 | 0.82 | ADRA2A (0.43) | TSHRNPC1RAB9ACYP1A2CYP3A4 | |
| Dexmedetomidine SCHEMBL22476080 | 0.82 | ADRA2A (0.40) | TSHRMEN1KMT2AAKR1B10TRPA1 | |
| Dexmedetomidine SCHEMBL22616265 | 0.81 | ADRA2A (0.42) | TSHRALDH1A1MEN1KMT2AMAPT | |
| Dexmedetomidine SCHEMBL22476078 | 0.80 | ADRA2A (0.41) | TSHRKDM4ELMNACYP1A2CYP3A4 | |
| Medetomidine SCHEMBL26432 | 0.79 | ADRA2A (0.50) | TSHRTRPA1CYP1A2CYP3A4CYP2C9 | |
| Medetomidine SCHEMBL787913 | 0.79 | ADRA2A (0.50) | TSHRTRPA1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3566703-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3566703-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3241553-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3241553-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2395999-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9555021-B2 | Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | ALLERGAN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160038466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9193690-B2 | Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | ALLERGAN, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080445-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120136035-A1 | 4-(1-(3-(HYDROXYMETHYL)-2-METHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | ALLERGAN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110301214-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLEGRAN, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010093930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093910-A1 | 4-(1-(3-(HYDROXYMETHYL)-2-METHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | ALLERGAN, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | OPRK1, OPRM1, OPRD1 | TSHR 4714/4885KDM4E 1982/4885ALDH1A1 999/4885 |
| US-20110301214-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | OPRK1, OPRM1, OPRD1 | TSHR 4714/4885KDM4E 1982/4885ALDH1A1 999/4885 |
| US-20150080445-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | OPRK1, OPRM1, OPRD1 | TSHR 4714/4885KDM4E 1982/4885ALDH1A1 999/4885 |
| US-20120136035-A1 | 4-(1-(3-(HYDROXYMETHYL)-2-METHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | OPRK1, OPRD1, TPMT | TSHR 1750/4885KDM4E 1708/4885ALDH1A1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.